Abstracts tagged "Anticardiolipin"

Abstract Number: 12 • 2013 ACR/ARHP Annual Meeting
Phosphatidiyserine-Prothrombin Complex (aPS/PT) IgG Antibodies Correlate With Lupus Anticoagulant and Specific Pregnancy Complications In Patients With Antiphospholipid Syndrome
Rohan Willis¹, Anne E. Tebo², Gabriella Lakos³, Michael Mahler³, Gary L. Norman³, Ware D. Branch⁴, Jane Salmon⁵, Marta M. Guerra⁶ and Silvia S. Pierangeli⁷, ¹Int Medicine/Rheumatology, University of Texas Medical Branch, Galveston, TX, ²Pathology, University of Utah, Salt Lake City, UT, ³Research, INOVA Diagnostics, San Diego, CA, ⁴Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁷Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Criteria laboratory tests for antiphospholipid syndrome (APS) include lupus anticoagulant (LAC) as well as IgG and IgM antibodies for cardiolipin and beta2 glycoprotein. Of…
Abstract Number: 13 • 2013 ACR/ARHP Annual Meeting
A MORE Specific Immunoassay For The Diagnosis Of APS
Claudia Grossi¹, Maria Borghi¹, Elizabeth Papalardo², Silvia S. Pierangeli³ and Pier Luigi Meroni⁴, ¹Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy, ²Louisville APL Diagnostics, Inc, Seabrook, TX, ³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy
Background/Purpose: Anticardiolipin (aCL) antibody assays are sensitive for the detection of antiphospholipid antibodies (aPL) in patients with the Antiphospholipid syndrome (APS) but are known to…
Abstract Number: 2455 • 2012 ACR/ARHP Annual Meeting
Establishment of Standardized International Units for IgG Anti-β₂glycoprotein Antibody Measurement
Rohan Willis¹, Claudia Grossi², Gabriella Lakos³, Pier Luigi Meroni⁴, Maria Borghi², Luis R. Lopez⁵, Corina Dima⁶, Marius C. Teodorescu⁷, Nicholas Ozarka⁷, Matthias Kast⁸, Nina Olschowka⁸, Alfredo Villarreal⁹, Maria Crisostomo¹⁰, Mike Watkins⁹, Wendy Vandam¹¹, Tony Prestigiacomo¹¹, Josep Puig¹², Kerrie Jaskal¹³, Roger Walker¹⁰, Sarah Paul⁹, T. Buckner¹⁴, Fernando S. Cavalcanti¹² and Silvia S. Pierangeli¹⁵, ¹Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy, ³Research, INOVA Diagnostics, San Diego, CA, ⁴Chair and Division of Rheumatology, Gaetano Pini Institute, University of Milan, Milan, Italy, ⁵Corgenix Inc, Broomfield, CO, ⁶Microbiology, Theratest Laboratories Inc, Lombard, IL, ⁷Microbiology, TheraTest Laboratories Inc, Lombard, IL, ⁸Phadia Thermofisher, Freiburg, MN, Germany, ⁹BioPlex Division, Bio-Rad Laboratories, Benicia, CA, ¹⁰Bio-rad Laboriatories, In, Bio-Rad Laboratories, Hercules, CA, ¹¹Bio-Rad Laboratories, Hercules, CA, ¹²Biokit, Barcelona, Spain, ¹³Instrumentation Laboratories, Bedford, MA, ¹⁴Corgenix, Broomfield, CO, ¹⁵Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Despite numerous efforts aimed at the standardization of assays for detection of anti-β2Glycoprotein I (aβ2GPI)antibodies, there are still concerns, including the type and…
Abstract Number: 2456 • 2012 ACR/ARHP Annual Meeting
Pro-Inflammatory and Pro-Thrombotic Markers in Persistently Antiphospholipid Antibody-Positive Patients with/without Systemic Lupus Erythematosus
Gurjot Basra¹, Doruk Erkan², Rohan Willis¹, JoAnn Vega³, Ana Laura Carrera Marin⁴, Patricia Ruiz Limon¹, Vijaya L. Murthy¹, Shraddha Jatwani¹, Neha Dang¹, Emilio B. Gonzalez¹ and Silvia S. Pierangeli⁴, ¹Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Research, Hospital for Special Surgery, New York, NY, ⁴Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Pro-inflammatory/thrombotic biomarkers (BMR), which are associated with aPL-mediated pathogenic effects in vitro/vivo, are also increased in aPL-positive patients. Here we examined whether those BMR…
Abstract Number: 2457 • 2012 ACR/ARHP Annual Meeting
An Open-Label Prospective Pilot Mechanistic Study of Fluvastatin in Persistently Antiphospholipid Antibody-Positive Patients
Doruk Erkan¹, Rohan Willis², JoAnn Vega³, Vijaya L. Murthy², Ana Laura Carrera Marin⁴, Gurjot Basra², Patricia Ruiz Limon², Emilio B. Gonzalez² and Silvia S. Pierangeli², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ³Research, Hospital for Special Surgery, New York, NY, ⁴Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Antiphospholipid antibodies (aPL) induce a pro-inflammatory and pro-thrombotic state by upregulating various cytokines, chemokines, and tissue factor (TF). Fluvastatin reduces TF expression and decrease…
Abstract Number: 1731 • 2012 ACR/ARHP Annual Meeting
IgA Anti-β₂glycoprotein I Antibodies Are Pathogenic in a Mouse Model of APS
Patricia Ruiz Limon¹, Zurina Romay-Penabad², Ana Laura Carrera Marin³, Elizabeth Papalardo⁴ and Silvia S. Pierangeli³, ¹Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Rheumatology/Dept Int Med, Univ of TX Medical Branch, Galveston, TX, ³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴Louisville APL Diagnostics, Inc, Seabrook, TX
Background/Purpose: Recently exclusive IgA anti-b2Glycoprotein I (ab2GPI) seropositivity - in the absence of any other antiphospholipid (aPL) antibodies- has been reported particularly in SLE patients. …
Abstract Number: 1736 • 2012 ACR/ARHP Annual Meeting
The Estimated Prevalence of Antiphospholipid Antibodies in the General Population with Pregnancy Morbidity
Cecilia B. Chighizola¹, Guilherme Ramires de Jesus², Laura Andreoli³, Alessandra Banzato⁴, Guillermo J. Pons-Estel⁵, Michael D. Lockshin⁶, Doruk Erkan⁷ and On Behalf of APS Action⁸, ¹Rheumatology, Istituto Auxologico Italiano, University of Milan, Milan, Italy, ²Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Rheumatology Unit, University of Brescia, Brescia, Italy, ⁴Department of Cardiac Thoracic and Vascular Sciences, (2) Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua Italy, Padua, Italy, ⁵Servicio de Enfermedades Autoinmunes, (4) Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, ⁶Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸APS ACTION, New York, NY
Background/Purpose: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) is an international research network created to conduct well-designed clinical trials in persistently…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].